Alnylam Pharmaceuticals
Stock Forecast, Prediction & Price Target
Alnylam Pharmaceuticals (ALNY) stock Price Target by analysts
$336.33
Potential downside: -25.11%
Alnylam Pharmaceuticals price prediction
What is Alnylam Pharmaceuticals stock analysts` prediction?
Alnylam Pharmaceuticals stock forecast: Based on 2 Wall Street analysts` predicted price targets for Alnylam Pharmaceuticals in the last 3 months, the avarage price target is $336.33, with a high forecast of $NaN. The average price target represents a -25.11% change from the last price of $449.12.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Alnylam Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Alnylam Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Whitney Ijem Canaccord Genuity | 0% 0/3 | 11 months ago | $336 -25.18% downside | $294.87 | StreetInsider | Previous targets (2) |
Whitney Ijem Canaccord Genuity | 0% 0/3 | 12 months ago | $366 -18.50% downside | $273.69 | StreetInsider | Previous targets (2) |
Tazeen Ahmad Bank of America Securities | 50% 1/2 | 12 months ago | $307 -31.64% downside | $274.91 | StreetInsider | Previous targets (1) |
Kostas Biliouris BMO Capital | 0% 0/2 | about 1 year ago | $300 -33.20% downside | $269.31 | StreetInsider | Previous targets (1) |
Luca Issi RBC Capital | 20% 1/5 | about 1 year ago | $300 -33.20% downside | $271.43 | StreetInsider | Previous targets (4) |
Salveen Richter Goldman Sachs | 0% 0/2 | about 1 year ago | $370 -17.61% downside | $262.7 | TheFly | Previous targets (1) |
Whitney Ijem Canaccord Genuity | 0% 0/3 | about 1 year ago | $357 -20.51% downside | $253.86 | StreetInsider | Previous targets (2) |
Esther Rajavelu UBS | 50% 1/2 | about 1 year ago | $288 -35.87% downside | $247 | StreetInsider | Previous targets (1) |
Luca Issi RBC Capital | 20% 1/5 | about 1 year ago | $265 -40.99% downside | $245.17 | TheFly | Previous targets (4) |
Paul Matteis Stifel Nicolaus | 0% 0/2 | about 1 year ago | $295 -34.31% downside | $247.4 | StreetInsider | Previous targets (1) |
Luca Issi RBC Capital | 20% 1/5 | over 1 year ago | $250 -44.33% downside | $222.9 | TheFly | Previous targets (4) |
Liisa Bayko Evercore ISI | 0% 0/1 | over 1 year ago | $260 -42.10% downside | $222.9 | TheFly | Previous targets (0) |
Andrew Galler Morgan Stanley | 0% 0/1 | over 1 year ago | $250 -44.33% downside | $224.7 | StreetInsider | Previous targets (0) |
Paul Matteis Stifel Nicolaus | 0% 0/2 | over 1 year ago | $247 -45.00% downside | $227.92 | StreetInsider | Previous targets (1) |
Patrick Trucchio H.C. Wainwright | 0% 0/1 | over 1 year ago | $400 -10.93% downside | $227.05 | TheFly | Previous targets (0) |
Luca Issi RBC Capital | 20% 1/5 | over 1 year ago | $235 -47.67% downside | $156.43 | StreetInsider | Previous targets (4) |
Kostas Biliouris BMO Capital | 0% 0/2 | over 1 year ago | $234 -47.89% downside | $156.59 | StreetInsider | Previous targets (1) |
Edward Tenthoff Piper Sandler | 50% 1/2 | almost 3 years ago | $253 -43.66% downside | $229.37 | TheFly | Previous targets (1) |
Olivia Brayer Cantor Fitzgerald | 100% 1/1 | about 3 years ago | $175 -61.03% downside | $145.85 | TheFly | Previous targets (0) |
Edward Tenthoff Piper Sandler | 50% 1/2 | over 3 years ago | $208 -53.68% downside | $135.83 | TheFly | Previous targets (1) |
Gary Nachman BMO Capital | 100% 1/1 | over 3 years ago | $175 -61.03% downside | $150.76 | TipRanks Contributor | Previous targets (0) |
Zhiqiang Shu Berenberg Bank | 100% 1/1 | over 3 years ago | $154 -65.71% downside | $150.76 | TipRanks Contributor | Previous targets (0) |
Luca Issi RBC Capital | 20% 1/5 | over 3 years ago | $225 -49.90% downside | $150.86 | TipRanks Contributor | Previous targets (4) |
Debjit Chattopadhyay Guggenheim | 100% 1/1 | over 3 years ago | $170 -62.14% downside | $142.51 | TheFly | Previous targets (0) |
Tazeen Ahmad Bank of America Securities | 50% 1/2 | over 3 years ago | $209 -53.46% downside | $130.12 | StreetInsider | Previous targets (1) |
Maury Raycroft Jefferies | 100% 1/1 | over 3 years ago | $205 -54.35% downside | $136.53 | TipRanks Contributor | Previous targets (0) |
Ritu Baral Cowen & Co. | 0% 0/1 | almost 4 years ago | $250 -44.33% downside | $186.42 | TheFly | Previous targets (0) |
Salveen Richter Goldman Sachs | 0% 0/2 | almost 4 years ago | $273 -39.21% downside | $187.01 | TheFly | Previous targets (1) |
Maneka Mirchandaney Evercore ISI | 100% 1/1 | almost 4 years ago | $190 -57.69% downside | $159.56 | TipRanks | Previous targets (0) |
Esther Rajavelu UBS | 50% 1/2 | almost 4 years ago | $211 -53.01% downside | $159.56 | StreetInsider | Previous targets (1) |
Alethia Young Cantor Fitzgerald | 0% 0/1 | almost 4 years ago | $275 -38.76% downside | $159.56 | TheFly | Previous targets (0) |
Gena Wang Barclays | 100% 1/1 | almost 4 years ago | $210 -53.24% downside | $162.14 | Investing | Previous targets (0) |
Alnylam Pharmaceuticals Financial Estimates
Alnylam Pharmaceuticals Revenue Estimates
Alnylam Pharmaceuticals EBITDA Estimates
Alnylam Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $844.28M N/A | $1.03B 22.87% | $1.82B 76.23% | Avg: $2.30B Low: $1.99B High: $2.59B avg. 25.84% | Avg: $3.09B Low: $2.59B High: $3.51B avg. 34.45% | Avg: $4.00B Low: $3.36B High: $4.55B avg. 29.61% | Avg: $5.06B Low: $4.25B High: $5.75B avg. 26.20% |
Net Income
% change YoY
| $-852.82M N/A | $-1.13B -32.63% | $-440.24M 61.08% | Avg: $-226.35M Low: $-472.14M High: $288.53M avg. 48.58% | Avg: $307.52M Low: $-101.17M High: $1.14B avg. 235.86% | Avg: $700.81M Low: $555.19M High: $824.99M avg. 127.89% | Avg: $1.29B Low: $1.02B High: $1.52B avg. 84.33% |
EBITDA
% change YoY
| $-709.12M N/A | $-894.43M -26.13% | $-258.24M 71.12% | Avg: $-1.76B Low: $-1.98B High: $-1.52B avg. -581.88% | Avg: $-2.36B Low: $-2.69B High: $-1.98B avg. -34.45% | Avg: $-3.06B Low: $-3.48B High: $-2.57B avg. -29.61% | Avg: $-3.87B Low: $-4.40B High: $-3.25B avg. -26.20% |
EPS
% change YoY
| -$7.2 N/A | -$9.3 -29.16% | -$3.52 62.15% | Avg: -$1.64 Low: -$3.78 High: $2.31 avg. 53.33% | Avg: $2.35 Low: -$0.81 High: $9.2 avg. 243.15% | Avg: $5.61 Low: $4.44 High: $6.6 avg. 138.59% | Avg: $10.34 Low: $8.19 High: $12.18 avg. 84.33% |
Operating Expenses
% change YoY
| $1.41B N/A | $1.65B 17.04% | $1.80B 8.85% | Avg: $2.43B Low: $2.10B High: $2.74B avg. 35.14% | Avg: $3.27B Low: $2.74B High: $3.71B avg. 34.45% | Avg: $4.23B Low: $3.56B High: $4.81B avg. 29.61% | Avg: $5.35B Low: $4.49B High: $6.07B avg. 26.20% |
FAQ
What is Alnylam Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 124.16% in 2025-2028.
We have gathered data from 19 analysts. Their low estimate is -472.14M, average is -226.35M and high is 288.53M.
What is Alnylam Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 29.02% in 2025-2028.
We have gathered data from 23 analysts. Their low revenue estimate is $1.99B, average is $2.30B and high is $2.59B.
What is Alnylam Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 129.85% in 2025-2028.
We have gathered data from 19 analysts. Their low earnings per share estimate is -$3.78, average is -$1.64 and high is $2.31.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Alnylam Pharmaceuticals stock. The most successful analyst is Whitney Ijem.